2. UroToday Home
  3. Video Lectures

Non-Muscle Invasive Bladder Cancer Videos

CORE-008 CX Early Efficacy and Tolerability Data - Aaron Berger
Non-Surgical Management of Non-Muscle Invasive Bladder Cancer: Surveillance, Chemoablation, and Office-Based Approaches - Katie Murray
First-Line Therapy Determines Bladder Preservation in High-Grade NMIBC - Peter Black
JCOG1019 Trial: Active Surveillance Versus BCG for T1 Bladder Cancer with Negative Second TUR - Hiroshi Kitamura
BOND-003 Cohort P Examines Gene Therapy for Papillary-Only BCG-Unresponsive Bladder Cancer - Vikram Narayan
Response-Guided Strategy Investigates Omission of Repeat TUR in High-Risk NMIBC - Roberto Contieri
Surgical Management of NMIBC: Comparing En Bloc to Standard Resection Techniques - Jeremy Teoh
Evaluating the Case Against Combining Immune Checkpoint Inhibitors with BCG in Non-Muscle-Invasive Bladder Cancer - Félix Guerrero-Ramos
Women's Bladder Cancer Program Addresses Sex-Specific Gaps in Care and Research - Armine Smith
Managing Radiation Toxicity After Trimodal Therapy for Bladder Cancer - Antoine Van Der Heijden & Neha Vapiwala
Multidisciplinary Teams to Address Quality and Documentation of Bladder Tumor Resection - Patrick Hensley
Bladder Preservation After Neoadjuvant EV+Pembrolizumab - Bogdana Schmidt & Fernando Maluf
Cystoscopy vs Urinary Markers: A Debate on Bladder Cancer Surveillance Strategies - Jeremy Teoh & Laura Mertens
Counseling Women with Bladder Cancer: Balancing Treatment Goals and Quality of Life - Sarah Psutka
BOND-003 Cohort C: Cystectomy Outcomes Following Cretostimogene in BCG-Unresponsive NMIBC - Gary Steinberg
Phase III Trial Compares BCG Strains and Priming in Non-Muscle-Invasive Bladder Cancer - Robert Svatek
Individual Patient Data Analysis Explores Benefit of Adding Immunotherapy to BCG in Bladder Cancer - Ashish Kamat
SURE-02 Trial Investigates Sacituzumab Plus Pembrolizumab in Bladder Preservation Approach - Andrea Necchi
Biomarker-Based Classification Evaluated for Predicting Progression in High-Risk NMIBC - Joep de Jong
Patient-Reported Outcomes in NMIBC Trials: A 30-Year Analysis of Incorporation Trends - Patrick Hensley
Women Leading Change in Bladder Cancer: Addressing Diagnostic Delays and Unique Needs - Jeannie Hoffman-Censits
ENVISION Trial Analysis: Reverse Thermal Gel with Mitomycin Outcomes by EORTC Risk Group – William Huang
RESECT Study Investigates Impact of Observation and Feedback on Surgeon Performance - Kevin Gallagher & Veeru Kasivisvanathan
Developing a Patient-Centered Decision Aid for Urinary Diversion Choices in Bladder Cancer - Divya Ajay
Exploring KDM6A as a Clinically Actionable Biomarker in Bladder Cancer - Sangeeta Goswami
A Multi-Center Study Examines Maintenance Schedules for Intermediate-Risk NMIBC - Roberto Contieri
Systematic Review of Cure Definitions in Early Bladder Cancer - Félix Guerrero-Ramos
AI Model PROGRxN-BCa Tested in Predicting Bladder Cancer Progression - Girish Kulkarni
DRIFT: A Floating Device for Intravesical Gemcitabine-Docetaxel Delivery - James Byrne
JSUO and IBCG Collaborate on a Global Standard for TURBT Surgical Checklists - Rikiya Taoka & Mikio Sugimoto
Evaluating an Integrated Electronic Health Record Pathway for Non-Muscle Invasive Bladder Cancer Care - Fed Ghali
Predicting Pelvic Recurrence in Bladder Cancer: A Five-Factor Risk Score - Vidit Sharma
Urine Tumor DNA as a Biomarker for High-Risk Bladder Cancer Recurrence and Guidance - Roger Li
Navigating Treatment Options and Trial Designs for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Vignesh Packiam
CISTO Study: Patient Preferences Drive Bladder Cancer Treatment Choice, Shaping Quality of Life Outcomes - Angela Smith
SunRISe-1 Cohort 4 Analysis: One-Year Disease-Free Survival in BCG-Unresponsive Papillary Bladder Cancer - Siamak Daneshmand
The Clinical Application of Circulating Tumor DNA in Bladder Cancer Prognosis and Surveillance - Nirmish Singla
Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka
Challenges and Management Strategies for BCG-Unresponsive Bladder Cancer - Frances Martin & Patrick Hensley
ALBAN Trial Analysis: Evaluating Atezolizumab Addition to BCG Therapy in High-Risk, Non-Muscle-Invasive Bladder - Morgan Rouprêt
Blue Light Cystoscopy Outcomes and Cost Analysis from the BRAVO Study - Ali Nasrallah
Subgroup Findings from CREST Trial in High-Risk Bladder Cancer - Gary Steinberg
Final Analysis of Phase 3 POTOMAC Study in High-Risk NMIBC - Maria De Santis
Phase 2 Formula-01 Study Evaluates DV Combined With BCG for HER2-High NMIBC - Xingliang Tan
IBCG Recommendations for Intermediate-Risk NMIBC Definitions and Management - Roger Li
Identifying an Aggressive Subgroup in Low-Grade Bladder Cancer with a Molecular Classifier - Ewan Gibb
Analysis of Three Trials Evaluating BCG Plus Checkpoint Inhibitors in Bladder Cancer - Peter Black
Phase II SURF302 Study Evaluating Oral FGFR3 Inhibitor Dabogratinib - Gautam Jayram
Biomarker Analysis from the SunRISe-1 Trial in BCG-Unresponsive CIS - Félix Guerrero-Ramos
Shifting From TURBT to Chemoablation in Low-Grade Intermediate-Risk NMIBC - Max Kates
CISTO Trial Examines One-Year Survival Between Bladder Removal and Sparing - John Gore
Cost-Effectiveness of Bladder Cancer Treatments Varies by Patient Scenario and Preference - Amanda Myers
Limitations of Urine-Based Biomarkers for Replacing Cystoscopy in Hematuria - Wei Shen Tan
Adjuvant Radiotherapy Evaluated for High-Risk Bladder Cancer After Cystectomy - Vedang Murthy
Assessment of Urine-Based Tests and Adjuncts in Bladder Cancer Guidelines - Laura Bukavina
Stage-Based Treatment for Non-Muscle Invasive Bladder Cancer - Ricardo Rendon
Treatment Options for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer - Kelly Stratton
SunRISe-1 Trial of the TAR-200 Gemcitabine Delivery System - Siamak Daneshmand
ZUSDURI™ FDA Approved for Low-Grade Intermediate-Risk Bladder Cancer - Mark Schoenberg
Analysis of Four-Tier Hybrid Grading System for Ta Non-Muscle-Invasive Bladder Cancer - Roberto Contieri
Guidelines for High-Risk Non-Muscle Invasive Bladder Cancer Treatment Options - Neal Shore
Technology-Driven Innovation in Bladder Cancer: Surgery, Surveillance, and Beyond – Saum Ghodoussipour
Economic Evaluation of Bladder Preservation vs. Radical Cystectomy - Daniel Joyce
Artificial Intelligence and Machine Learning in Bladder Cancer Pathology and Clinical Decision-Making - Hikmat Al-Ahmadie & Alexandre Zlotta
Management Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer - Roberto Contieri
ABLE-22 Trial: Comparing Combination Therapies for BCG-Unresponsive Bladder Cancer - Siamak Daneshmand
An Artificial Intelligence Predictive Biomarker for Response to BCG vs Gemcitabine-Docetaxel for High Grade NMIBC - Vignesh Packiam
Treatment Dilemmas for BCG-Unresponsive Bladder Cancer in Canada and Beyond - Wassim Kassouf
Computational Histology AI's Potential in Refining NMIBC Prognostication - Bryn Launer
Optimizing Patient Selection and Treatment Timing for Emerging Intravesical Therapies - Vignesh Packiam
The State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer - Leslie Ballas, Parminder Singh & Mark Tyson
Low-Grade Ta Bladder Tumors Show Unexpected Metastatic Potential in Long-Term Study - Alexandre Zlotta
Blue Light Cystoscopy Detects Hidden Bladder Cancer After Induction Therapy - Vignesh Packiam
Event-Free Survival and Emerging Immunotherapy Approaches in High-Risk NMIBC - Neal Shore
SSANTROP Trial: Evaluating Sasanlimab Plus Sacituzumab Govitecan in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joaquim Bellmunt
Cretostimogene Expanded Access Program Provides Alternative for BCG-Unresponsive Bladder Cancer Patients - Wassim Kassouf
Tumor Characteristics and Response Patterns in the ENVISION UGN-102 Trial - John Sfakianos
Computational Histology AI Guides Treatment Selection for Bladder Cancer Patients - Vignesh Packiam
Sasanlimab Plus BCG Improves Event-Free Survival in High-Risk NMIBC: First Interim Trial Results, Journal Club - Rashid Sayyid & Zachary Klaassen
AUA 2025 Highlights: Advances in Non-Muscle Invasive Bladder Cancer - Patrick Hensley & Janet Kukreja
Sasanlimab Immunotherapy + BCG in BCG-Naive Bladder Cancer - Sam Chang
Examining Under-Staging in BCG-Unresponsive Bladder Cancer Patients Undergoing Radical Cystectomy - Katharina Oberneder
Efficacy of TAR-200 in Non-Muscle Invasive Bladder Cancer: 1-Year Outcomes - Joseph Jacob
ADVANCED-2 Trial: TARA-002 in BCG-Naive High-Risk NMIBC - Brian Mazzarella
PIVOT-006 Trial: Cretostimogene Grenadenorepvec for Intermediate-Risk Non-Muscle Invasive Bladder Cancer - Max Kates
BCG Efficacy in Bladder Cancer Amid Emerging Immunotherapy Combinations - Joshua Meeks & Benjamin Pradere
BCG-Unresponsive Bladder CIS: Real-World Data Reveals High Recurrence and Treatment Gaps - Stephen Williams
MoonRISe-1 Trial: Evaluating TAR-210 for FGFR-Altered Intermediate-Risk NMIBC - Roger Li
Multicenter European Trial Investigates Gem/Doce for Non-Muscle Invasive Bladder Cancer - Pietro Scilipoti
International Validation of AI Tool for Stratifying Bladder Cancer Progression Risk - Jethro Kwong
AI Risk Calculator Outperforms EAU Models for Bladder Cancer Prognosis - Alexandre Zlotta
Active Surveillance vs TURBT for Low-Grade Ta Bladder Cancer - Morgan Rouprêt & Laura Bukavina
Practice-Changing Advances in Urothelial Cancer: Highlights Across Disease States - Alice Yu
SunRISe-1 Trial Shows TAR-200 Efficacy in BCG-Unresponsive Bladder Cancer - Felix Guerrero-Ramos
CISTO Study: Comparing Cystectomy vs. Bladder-Sparing Therapy for Recurrent NMIBC - John Gore
Real-World Implementation of Biomarkers for Microhematuria Workup - Ronald Loo & Christopher Filson
AUA Microhematuria Guidelines 2025 - Daniel Barocas
Real-World Data Improves NMIBC Risk Assessment with Blue Light Technology - Siamak Daneshmand & Boris Gershman
Platform Reduces Unnecessary Cystoscopies for Hematuria Patients - John Sfakianos
Checkpoint Inhibition in BCG-Naive NMIBC: Mechanisms and Emerging Evidence - Matthew Galsky
CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder Cancer - Trinity Bivalacqua
CORE-008 Cohort B: Cretostimogene for BCG-Exposed NMIBC – Trial Activation & Clinical Goals - Trinity Bivalacqua
Management Strategies for Low-Grade Intermediate-Risk Bladder Cancer - Sarah Psutka
CORE-008 Cohort A: Cretostimogene in BCG-Naïve High-Risk NMIBC – Trial Design & Update - Trinity Bivalacqua
BOND-003 Cohort C Trial Results for Cretostimogene Grenadenorepvec in BCG-Unresponsive Bladder Cancer - Mark Tyson
CUT-less Trial Aims to Eliminate Secondary TURBT in Non-Muscle Invasive Bladder Cancer - Francesco Del Giudice
Evaluating Risk Stratification Models for Blue Light Cystoscopy in Bladder Cancer - Sia Daneshmand & Boris Gershman
Streamlining Intravesical Therapy: Practical Insights for BCG-Unresponsive NMIBC - Patrick Hensley
Biomarkers for Gemcitabine Docetaxel in Non-Muscle Invasive Bladder Cancer - Vignesh Packiam
Advancing Microhematuria Evaluation: The Impact of Urinary Biomarkers and Updated Guidelines - Jay D. Raman & Yair Lotan
Refining Risk in NMIBC: Intermediate Stratification, TURBT Quality, and Emerging Options - Katie Murray
Predicting BCG Therapy Response in High-Grade Non-Muscle Invasive Bladder Cancer - Weranja Ranasinghe
Managing BCG-Unresponsive Bladder Cancer: Balancing Bladder Preservation and Cystectomy - Paolo Gontero & Maria Carmen Mir
Risk Stratification for Active Surveillance in Low and Intermediate-Risk Bladder Cancer - Marco Moschini
Cretostimogene Grenadenorepvec Complete Response in BOND-003 Cohort C - Trinity Bivalacqua
Evolving Treatment Landscape for Non-Muscle Invasive Bladder Cancer Beyond BCG - Bogdana Schmidt
ENVISION Trial Evaluates UGN-102 for Recurrent Low-Grade NMIBC Bladder Cancer - Sandip Prasad
Genomic Landscape of Non-Muscle Invasive Bladder Cancer from UROMOL Consortium - Lars Dyrskjøt
Primary Chemo Ablation with UGN-102 for Recurrent Low Grade Bladder Cancer in the ENVISION Trial - Sandip Prasad
Detecting ctDNA in High-Risk Non-Muscle Invasive Bladder Cancer - Dan Isaac
Immune Infiltration Gene Signatures Predict Response to Gemcitabine Docetaxel vs BCG in Bladder Cancer - Michael O'Donnell
Circulating and Urinary Tumor DNA in Bladder Cancer Treatment and Surveillance - Alan Tan
Cretostimogene Grenadenorepvec Expanded Access Program for BCG-Unresponsive Bladder Cancer - Sarah Psutka
Germline Testing for Risk Stratification in Low-Grade Bladder Cancer on Active Surveillance - Roberto Contieri
Bladder Cancer Risk Stratification Using Non-Coding RNA - Yair Lotan
Intravesical Antibody-Drug Conjugates for Bladder Cancer - Di Maria Jiang
Advances in Non-Muscle Invasive Bladder Cancer Treatment Options - Bogdana Schmidt
Global BCG Shortage Impacts Treatment for High-Risk Bladder Cancer Patients - Jens Bedke
Registry Data Shows Risk Migration With Blue Light Cystoscopy - Alireza Ghoreifi & Siamak Daneshmand
Dual Immune Activation with EG-70 Targets Non-Muscle Invasive Bladder Cancer - Vikram Narayan
Real-World Data on Nadofarogene Firadenovec for BCG-Unresponsive Bladder Cancer - Mark Tyson & Jacob Moyer
What Everyone’s Talking About: Highlights from SUO 2024 - Amy Luckenbaugh
Bladder-Sparing Therapy vs Upfront Cystectomy: Long-Term Outcomes in BCG-Unresponsive Bladder Cancer - Jacob Taylor
Smoking Cessation as a Precision Cancer Care Intervention in Urologic Oncology - Richard Matulewicz
BCG-Unresponsive Bladder Cancer Study Examines Risks of Bladder-Sparing Therapies for T1 Disease - Yair Lotan
Sequential Gemcitabine and Docetaxel Examined in BCG-Unresponsive Bladder Cancer Patients - Yair Lotan
FGFR3 Inhibition in Urothelial Cancer Advances with Erdafitinib and TAR-210 Trials - Gopa Iyer
Phase II Trial Explores Gemcitabine Plus BCG for BCG-Exposed Bladder Cancer - Eugene Pietzak & Gal Wald
The Top 10 Reasons Why BCG (as a Monotherapy) Will Cease to Exist - Cheryl Lee
Moving Beyond Single Arm Trials in BCG Unresponsive Cancer Care - Joshua Meeks
Safety and Tolerability of TAR-200 Monotherapy in Patients with Bacillus Calmette-Guerin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer in SUNRISE-1 - Siamak Daneshmand
High Risk Bladder Cancer Treatment Outcomes After Additional BCG - Amanda Myers
CORE-008 Cohort B Tests Cretostimogene’s Efficacy in High-Risk, Non-BCG-Responsive Disease - Trinity Bivalacqua
CORE-008 Cohort A Tests Oncolytic Immunotherapy in BCG-Naive High-Risk Bladder Cancer - Trinity Bivalacqua
Real-World Treatments Following BCG Induction in Patients with NMIBC: A US Claims Analysis - Amanda Myers
Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski
Advancing Treatment for BCG-Unresponsive Bladder Cancer - Eugene Pietzak
BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat
Gemcitabine and Docetaxel Combination Offers Promising Alternative to BCG in Bladder Cancer Treatment - Sunil Patel & Max Kates
BRAVO Trial Highlights Improved Detection Reduces Bladder Cancer Recurrence - Ali Nasrallah
JCOG1019 Trial Examines Watchful Waiting vs BCG for High-Grade T1 Bladder Cancer - Hiroshi Kitamura
Bladder Cancer Research Explores Fecal Transplants and Nutritional Strategies - Laura Bukavina
SunRISe-1 Trial Advances Bladder Cancer Treatment with TAR-200 - Michiel Van der Heijden
Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis
Harnessing Artificial Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment - David McConkey
Patient Perspectives on Bladder Cancer: Balancing Treatment Options and Shared Decision-Making - Roger Li
Advancing Radiopharmaceuticals: Targeting Strategies and Isotope Selection in Cancer Therapy - John Babich
Stratification Tool Identifies High-Risk Patients Within Heterogeneous Bladder Cancer Group - Francesco Soria
Novel Therapies for Non-Muscle Invasive Bladder Cancer: Expert Review - Felix Guerrero-Ramos
ctDNA in Non-Muscle Invasive Bladder Cancer: Screening & Prognosis - Saum Ghodoussipour
Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer - Beyond the Abstract
Novel CD40 Antibody Treatment for BCG-Unresponsive Bladder Cancer - Bernard Bochner
Orion Study Evaluates Paclitaxel Conjugate for BCG-Unresponsive Cancer - Sunil Patel
MoonRISe-1: Evaluating TAR-210 for Intermediate-Risk Non-Muscle-Invasive Bladder Cancer - Roger Li
SunRISe-5 Trial: Evaluating TAR-200 for Recurrent High-Risk Non-Muscle Invasive Bladder Cancer - Sima Porten
Adequate BCG Therapy for Very High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Analysis - José Daniel Subiela Henriquez
Bridging the Gap in Microhematuria Evaluation: A Discussion on the STRATA Trial - Yair Lotan
CORE-001 Study Demonstrates Promising Results for Bladder Cancer with Cretostimogene Grenadenorepvec and Pembrolizumab - Trinity Bivalacqua & Roger Li
Apalutamide for Preventing Bladder Cancer Recurrence: A Proof-of-Principle Trial - Edward Messing
Innovative Trials Highlight Progress in Treating Urothelial Carcinoma at AUA 2024 - Karim Chamie
KEYNOTE-676 Cohort A: Pembrolizumab + BCG for Previously BCG-Treated NMIBC - Neal Shore
AUA 2024 Urothelial Carcinoma Highlights - Woodson Smelser
Immunotherapy Advancements in Bladder Cancer: Clinical Trials, Early Intervention, and Toxicity Management - Matt Galsky & Neal Shore
SSANTROP Trial: Evaluating Sacituzumab Govitecan and Sasanlimab for BCG-Unresponsive Bladder Cancer - Oscar Rodriguez-Faba
Managing Variant Histology in High-Risk Non-Muscle Invasive Bladder Cancer - Michael Cookson & Paolo Gontero
Leveraging AI Biomarkers to Navigate the Evolving Landscape of Bladder Cancer Treatment - Stephen Williams
AI-Based Assessment Tool for Predicting BCG Response in Bladder Cancer Patients - Yair Lotan
Navigating the Expanding Landscape of BCG-Unresponsive NMIBC Treatment Options - Mark Tyson
VA BRAVO 2 Study: Blue Light Cystoscopy Improves Outcomes in NMIBC Patients in Equal Access Setting - Stephen B Williams
SunRISe-3 Trial: TAR-200 with or without Cetrelimab vs. BCG for BCG-Naive High-Risk NMIBC - Sam Chang
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer AUA/SUO Guideline - 2024 Amendment - Jeffrey Holzbeierlein
Patient-Driven Outcomes in the CISTO Trial for High-Grade Non-Muscle Invasive Bladder Cancer - Angela Smith & John Gore
Sequential Gemcitabine and Docetaxel Shows Promise for Intermediate-Risk NMIBC - Vignesh Packiam
Intravesical Gemcitabine-Docetaxel Shows Durable Response in Recurrent High-Risk NMIBC After BCG - Mark Preston
Age Alone Should Not Preclude BCG Therapy in NMIBC - Ashish Kamat
Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC: A Discussion on the BOND-003 and CORE1 Trials - Trinity Bivalacqua
Understanding BCG Unresponsive NMIBC: Patient Perspectives, Treatment Options, and Clinical Guidance - Gautam Jayram
Understanding Risk Stratification in Non-Muscle Invasive Bladder Cancer: Applying AUA Guidelines in Clinical Practice - Neal Shore
Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes - Kyle Richards
Combining Pembrolizumab and BCG Immunotherapies: The KEYNOTE-676 Trial in High-Risk NMIBC - Neal Shore
Treatment Options Expand for BCG Unresponsive Bladder Cancer - Mark Tyson
PIVOT-006 - A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer - Mark Tyson
Bladder Cancer: En Bloc Resection Technique Shows Promise - David D'Andrea
Chinese Trial Blue Light Cystoscopy Superior for Bladder Cancer Detection - Hongxian Zhang
BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC - Mark Tyson
Exploring Promising Therapies and Genomic Insights in Bladder Cancer Research - Laura Bukavina
Enhancing Bladder Cancer Diagnosis and Management with Advanced Visualization Techniques - Stephen B. Williams
Consensus Recommendations to Optimize Low and Intermediate-Risk Bladder Cancer Studies, Journal Club - Rashid Sayyid & Zachary Klaassen
Leaders Establish Consensus Criteria for High-Risk Bladder Cancer Trials, Journal Club - Rashid Sayyid & Zachary Klaassen
Advances Bring Immunotherapy and Targeted Therapy Options for Non-Muscle Invasive Bladder Cancer - Kriti Mittal & Guru Sonpavde
Exploring Bladder Cancer Innovations: A Deep Dive into ESMO 2023 - Morgan Rouprêt
Operationalizing Blue Light in Your Practice - Gautam Jayram
Cretostimogene Grenadenorepvec Therapy Aims to Fill an Unmet Need in the Bladder Cancer Armamentarium - Robert Svatek
Novel Gene Therapy Shows Efficacy and Tolerable Safety Profile for Patients with Treatment-Resistant Bladder Cancer - Trinity Bivalacqua
The Promise, Potential, and Practicality of Cxbladder in Modern Urologic Oncology - Mark Tyson, II
A New Approach to Bladder Cancer: The ATLAS Trial's Exploration of UGN-102 and TURBT, Journal Club - Rashid Sayyid & Zachary Klaassen
Blue Light Cystoscopy Delays Time To Recurrence in NMIBC Patients Treated in a Real-World Setting - Sia Daneshmand
Exploring Erdafitinib: A Breakthrough in Non-Muscle Invasive Bladder Cancer Treatment - Siamak Daneshmand
Improving Bladder Cancer Treatment: An Insight into Vanderbilt's Innovative BCG Clinic - Meredith Donahue & Tara Cumming
Pembrolizumab's Impact on Cystectomy-Free Survival in BCG Unresponsive Bladder Cancer from the KEYNOTE-057 Trial - Girish Kulkarni
Managing Intermediate Risk Bladder Cancer: Treatment Strategies and Surveillance - Paolo Gontero & Gary Steinberg
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
TAR-200 in Combination with Cetrelimab for BCG Unresponsive Bladder Cancer (SunRISe-1) - Siamak Daneshmand
Optimizing BCG Therapy in Bladder Cancer: Expert Insights on Managing Toxicity and Maximizing Efficacy - Badrinath Konety & Wassim Kassouf
Debating Treatment Options for Very High-Risk Non-Muscle-Invasive Bladder Cancer: BCG vs. Radical Cystectomy - Morgan Rouprêt & Laura Mertens
Gene Therapy and Pembrolizumab in BCG-Unresponsive CIS-Containing Population: Updated Results, Efficacy, and Correlative Studies - Roger Li
En Bloc Resection vs. Standard Resection for Bladder Tumors: Multicenter Trial Results and Clinical Considerations - Jeremy Teoh
Long-Term Survival Outcomes in Patients with BCG Unresponsive Non-Muscle Invasive Bladder Cancer: Evaluating Bladder-Sparing Treatment - Wei Shen Tan
Gene Therapy for Non-muscle Invasive Bladder Cancer - Roger Li
Gemcitabine and Docetaxel Therapy Associated with Better Outcomes than BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study - Vignesh Packiam
The Importance of Proper Transurethral Resection of Bladder Tumors (TURBT) in Bladder Cancer Treatment - Arnulf Stenzl
Results from Cohort B of the Phase 2 KEYNOTE-057 Trial, Pembrolizumab Monotherapy for Patients with High-Risk Non–muscle-Invasive Bladder Cancer Unresponsive to BCG - Andrea Necchi
Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group: Intermediate-risk Non-muscle-invasive Bladder Cancer - Wei Shen Tan
HIVEC-II Phase 2 Trial Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk NMIBC - Wei Shen Tan
Clinical Perspective on Recurrence Mechanisms of Non-muscle Invasive Bladder Cancer – Jeremy Teoh
The Clinical Benefits of Blue Light Cystoscopy in the Ambulatory Surgical Centers - Neal Shore
Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose
Blue Light Powered by Saphira® for the Detection of Non Muscle-Invasive Bladder Cancer - Max Kates & Trinity J. Bivalacqua
Non Muscle-Invasive Bladder Cancer: An Overview of Potential New Treatment Options - Beyond the Abstract
Pembrolizumab Monotherapy for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to BCG the KEYNOTE-057 Study, Journal Club – Christopher Wallis & Zachary Klaassen
Advances in Treatment Options for BCG Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer - QUILT 3.032 - Sam Chang
BCG Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer - Seth Lerner
Demonstrated Underuse of Blue Light Cystoscopy for Bladder Cancer in the United States - Patrick Lewicki
The Association of Smoking Status with Recurrence in Patients with Predominantly High-Risk Recurrent NMIBC - Richard Matulewicz
The Natural History of High-Risk NMIBC: Novel Therapies vs Cystectomy - Angela Smith
The Role of Radiology and Radiomics in Staging & Risk Stratification of NMIBC - Manjiri Dighe
Novel Immune Checkpoint Axis To Understand BCG Resistance and Improve Treatment in Non-muscle Invasive Bladder Cancer - Amir Horowitz & John Sfakianos
Conundrums in Bacillus Calmette Guerin (BCG) Unresponsive Nonmuscle Invasive Bladder Cancer Trials - Roger Li
Combining BCG and Intravesical Gemcitabine (GBIG) for Patients with BCG-Relapsing High-Grade NMIBC Cancer A Phase 1/2 Trial- Eugene Pietzak
The Use of Blue Light Cystoscopy for Both Hospital and Outpatient Clinic - Yair Lotan and Daniel Parker
Improved Tumor Visibility, Detection Rate and Reduced Recurrence Rates After TURBT - Siamak Daneshmand and Marek Babjuk
Molecular Landscape of NMIBC and Risk Factors for Progression A Lecture & Discussion - Eugene Pietzak
Trained Immunity as a Molecular Mechanism for BCG Immunotherapy - Sita Vermeulen
How to Define Treatment Failure After BCG Treatment for Nonmuscle-Invasive Bladder Cancer - Peter Black
High-Risk Non Muscle-Invasive BCG Unresponsive Bladder Cancer - Molecular Subtypes - Woonyoung Choi
Adherence to Guidelines-Based Management of Non-Muscle Invasive Bladder Cancer Among Society of Urologic Oncology (SUO) Members - Justin T. Matulay
Pembrolizumab in the BCG-unresponsive NMIBC Patients - Arjun Balar